TG THERAPEUTICS INC. - COMMON STOCK

31.26

24-January-25 16:45:00

15 minutes delayed

Stocks

+2.22

+7.64%

Today's range

28.44 - 31.27

ISIN

N/A

Source

NASDAQ

TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

04 Mar 2021 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results

02 Mar 2021 07:00:01 By Nasdaq GlobeNewswire
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update

26 Feb 2021 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology

23 Feb 2021 07:30:00 By Nasdaq GlobeNewswire
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

05 Feb 2021 13:54:45 By Nasdaq GlobeNewswire
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference

15 Jan 2021 07:00:00 By Nasdaq GlobeNewswire
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

08 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

<<
<
4
5
6
7
8
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.